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HIV infects more than 15,000 people every day. 
Most of these new infections are sexually 
transmitted and, so, compounds acting at a 
mucosal level and impeding infection would 
have a major epidemiological impact. Infections 
can be prevented by vaccines or by substances 
that block the penetration of pathogens in the 
body. In the first case we use adjuvanted antigens 
to elicit an immune response that will be able to 
avoid the insurgence of disease. It is important 
to notice that vaccines do not necessarily prevent 
infection (sterilizing immunity). Rather, these 
compounds impede disease: vaccine-stimulated 
immune responses modify the natural history of 
infection, avoiding the appearance of full-blown 
disease. Notably, with the exception of the 
results for the recent RV144 trial, the so-called 
‘Thai trial’ [1,2], which showed a very modest 
possible preventative effect, no vaccine has 
worked to impede HIV infection, and no 
effective vaccine is foreseeable in the near future. 
The second way to prevent infection is to 
block the penetration of a pathogen in the body. 
This modality does not imply active participa-
tion of the immune response; rather, physical 
and/or chemical means are used to impede the 
contact between pathogens and the host cell, 
and the subsequent penetration of the pathogen 
into such cells. In the case of HIV, the simplest 
preventative device is a condom. If properly 
used, condoms are highly effective in imped-
ing infection. Nevertheless, possible ethical 
considerations aside, cultural factors often keep 
men and women from using condoms, or women 
from asking their partners to use such devices, 
in many parts of the world. Finally, it has been 
repeatedly shown that reduced risk of HIV 
transmission is only associated with consist-
ent but not with occasional condom use. These 
considerations, the evidence of the ever-growing 
spread of new infections despite the availability 
of condoms and the objective difficulty in 
designing effective vaccines, led to the explo-
ration of the ability of microbicides to prevent 
sexual transmission of HIV [3–7]. Microbicides 
can be classified into five different groups: 
n	Surfactants; 
n	Vaginal milieu protectors; 
n	Viral entry inhibitors; 
n	Agents that target viral replication (reverse 
transcriptase inhibitors); 
n	Other compounds, whose mechanisms 
are unknown [4].
Surfactants can disrupt membranes non-
specifically and have been evaluated as topical 
microbicides. The protectors of vaginal milieu 
either operate as direct acidifying agents or as 
enhancers of lactobacilli production. Inhibitors 
of viral entry are a broad class of molecules, 
which can target either host cells or viral targets, 
and can block different steps of the pathways 
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used by HIV to cross mucosal barriers and to 
infect CD4+ lymphocytes, (e.g., the attach-
ment of HIV to host cells, the fusion of virus 
and host cell membranes, or the entry of HIV 
into host cells). 
More than 70 preclinical and 50 clinical tri-
als have been performed using compounds that 
fall in each of the five classes. In the preclinical 
Phase, in vitro assays and cervical explants mod-
els are used; some clinical experimentation has 
proceeded to Phase III, the evaluation of possible 
efficacy. In brief, none of the compounds that 
reached Phase III has demonstrated any effect 
on the prevention of infection [8–10].
HIV entry process & potential 
molecular targets for antiviral therapy 
HIV entry in CD4+ cells is a very com-
plex process that proceeds through a series 
of steps (FiguRe 1):
n	gp120, expressed on the viral surface, binds to 
the CD4 molecule present on host cells; 
n	This process induces a conformational change 
in gp120 that allows it to bind either CCR5 
or CXCR4, the main co-receptors for HIV; 
n	At this point, a rearrangement in a second 
viral protein, gp41, exposes on the surface of 
HIV a ‘fusion peptide’; 
n	The fusion peptide activates the complex 
fusion between the virus and the host 
cell membranes. 
In 2000, it was suggested that gp120 rec-
ognition at the mucosal level by the dendritic 
cell membrane lectin, specific ICAM-3 grab-
bing nonintegrin (DC-SIGN) may contribute 
to infection by promoting viral transmission 
and/or by inducing a signaling cascade, which 
results in immunosuppression [11–17].
Based on previously described steps, mol-
ecules binding to the host cell receptors CD4, 
CCR5, CXCR4, or possibly to DC-SIGN, 
could act as inhibitors of viral entry and stop 
the initial events leading to productive infection. 
A similar effect can be obtained by targeting 
the viral envelope and blocking, for instance, 
gp120 or the ‘fusion peptide’. All these are, as a 
consequence, very interesting approaches for the 
prevention of infection [18–23]. 
Indeed, as will be discussed in the follow-
ing sections, much research has been dedicated 
to the discovery of entry inhibitors and many 
candidates have emerged for drug develop-
ment. Negatively charged polyanions capable 
of binding to the surface of HIV were found 
to prevent infection in vitro. The fact that 
these compounds, besides being effective 
in vitro, are also easy to produce and economi-
cal, made them perfect potential candidates. 
Nevertheless, clinical trials of polyanions, 
including dextran sulfate and cellulose sulfate, 
failed to demonstrate any protection in vivo 
and, rather disappointingly, even increased 
plasma HIV viral load of infected individuals. 
Similarly, recent results from a Phase III clinical 
trial of the anionic inhibitor PRO-2000 have 
been disappointing [24]. 
Lectins targeting viral glycoproteins and 
potentially able to inhibit the binding process 
between receptors at the target cell membranes 
and the virus at the initial steps of infection, 
have been proven to be efficient in vitro, but 
their ability to modulate HIV infection in vivo 
has not yet undergone any clinical trial. Human 
and/or humanized monoclonal antibodies 
endowed with the ability to bind the CD4 bind-
ing domain and neutralize viral infectivity have 
been tested in vitro and in macaque models. In 
the animal model, these antibodies (e.g., B12, 
2F5, 2G12 and 4E10) showed a promising, 
although not total, ability to prevent infection 
(clinical trials have not yet been started). CCR5 
inhibitors, the newest class of antivirals used in 
clinical practice, are potentially very impor-
tant, as viruses that utilize this co-receptor are 
associated with almost the totality of mucosally 
transmitted HIV infections. CCR5 inhibitors 
were tested in the macaque model and were 
shown to effectively block vaginal infection 
(clinical trials based on the utilization of these 
molecules as mucosal tools to prevent infection 
have not yet started). Notably, infection can 
also be prevented in vitro by the use of high 
doses of RANTES, the chemo kine that binds 
CCR5. This observation led to the develop ment 
of a number of RANTES analogues that are 
endowed with potent anti viral activity. Some 
of these analogues have been shown to protect 
macaques against vaginal infection. Finally, 
peptides designed to interfere with the pro-
cesses resulting in the exposure of the fusion 
peptide on the surface of HIV (e.g., C52L) can 
convincingly prevent infection in the macaque 
model. Nevertheless, the effect is only observed 
in the presence of extremely elevated (100 mM) 
concentrations of drug. 
The development of compounds with the 
ability to prevent mucosal infection has also 
been slowed down by a number of other practical 
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issues. To summarize, an effective compound, 
besides being able to prevent infection, will also 
have to be: 
n	Safe and nontoxic;
n	Devoid of inflammatory activity;
n	Resistant to seminal fluid, to vaginal pH and 
body temperature;
n	Easy and simple to use (e.g., non oily 
and nonleaking);
n	Economical;
n	Simple to produce and store;
n	Endowed with durable activity.
Finally, even if receptive anal intercourse (RAI) 
is less frequent than vaginal intercourse (RVI), the 
median estimate of transmission risk for RAI is 
approximately 20-fold higher than that observed 
for RVI. These considerations indicate that the 
design of compounds able to prevent sexual trans-
mission of HIV altogether will need to take into 
account the necessity of protecting both the geni-
tal tract and the rectum. In the following sections 
we will discuss literature data concerning the dis-
covery and development of HIV entry inhibitors. 
Molecules will be grouped according to the loca-
tion of their target either on the host cell mem-
brane or the viral envelope. Finally, recent reports 
exploring the potential for the combination of 
diverse entry inhibitors and of entry inhibitors 
with other microbicides will be discussed. 
Host cell targets
	n CD4 inhibitors
CD4 is the main receptor for HIV-1 entry and, 
as a consequence, is a privileged target for strat-
egies for preventing the infection of target cells. 
However, most antiviral compounds were targeted 
against the CD4 binding site of gp120 rather than 
against CD4 itself (gp120-targeting compounds 
are reviewed in the appropriate section). One of 
the few inhibitors targeting CD4 is an anti-CD4 
humanized monoclonal antibody, known as ibal-
izumab or TNX-355  [25,26]. This molecule was 
developed as a potent in vitro inhibitor of HIV and 
has successfully completed Phase II clinical trials. 
Ibalizumab does not work by preventing gp120 
binding to CD4, but appears to decrease the flex-
ibility of CD4 and to hinder access of CD4-bound 
gp120 to the CCR5 and CXCR4 co-receptors. 
Recently, a bifunctional molecule comprising ibal-
izumab and two fusion inhibitor peptides has been 
described [27]. This novel bifunctional inhibitor 
was reported to display improved potency and 
favorable pharmacokinetic properties and may 
offer a novel approach to block both CCR5- and 
CXCR4-using viral variants.
	n Co-receptor inhibitors
The most important HIV-1 entry inhibitors tar-
geting one of the cell membrane co-receptors 
(CXCR4 and CCR5) are shown in Table 1. 
Antagonists of the CCR5 co-receptor were 
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Figure 1. HIV-1 entry steps and some potential targets. 
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investigated more thoroughly because indi-
viduals carrying a natural deletion (Δ32) in the 
CCR5 gene were found to be highly resistant to 
infection by CCR5-tropic strains and apparently 
healthy [28]. Furthermore, with few well-docu-
mented exceptions, primary infection is only 
supported by CCR5-directed strains of the virus. 
Tropism switch was found to occur in a high 
number of HIV infections and CXCR4-tropic 
variants may emerge when the CCR5-tropic 
virus is suppressed. This phenomenon, is never-
theless seen in the chronic phase of HIV infec-
tion only. In addition, systemic use of CXCR4 
antagonists is likely to lead to adverse effects by 
suppressing the physiological functions of this 
receptor, which is involved with the migration 
and development of hematopoietic cells. Hence, 
research on HIV entry inhibitors has focused 
mostly on CCR5 antagonists. 
Nonetheless, CXCR4 antagonists have 
also been investigated. In particular, two 
compounds have been described, AMD3100 
(Plerixafor) [29] and KRH-1636 [30] (entries 
1 & 2; Table 1, FiguRe 2), the most advanced 
of which, AMD3100, was found to possess lit-
tle antiviral activity, but was approved by the 
US FDA (December 2008) for stem cell mobi-
lization [31]. It was recently reported that the 
Cu2+ complex of AMD3100 shows improved 
potency relative to the starting compound, 
which was related to the increased residence 
time of the copper complex on CXCR4 [32]. 
Recent investigations focused on the optimiza-
tion of a previous lead (AMD070; FiguRe 2) [33] 
have led to the identification of an orally 
bioavailable compound with subnanomolar 
anti-HIV-1activity (1; FiguRe 2) [34].
Many CCR5 small-molecule antagonists 
have been reported [22,23,35–37]. Early attempts 
included Takeda’s TAK-779 [38,39] and Merck’s 
CMPD-167 (Table 1; entry 3&4) [40,41]. Three 
compounds, maraviroc [42,43], vicriviroc [44,45] 
and aplaviroc [46] have reached clinical trials 
(entries 5–7; Table 1 & FiguRe 2). Aplaviroc 
belongs to a class of spirodiketopiperazine deriva-
tives (FiguRe 2). Its development was halted in 
Table 1. HIV-1 entry inhibitors targeting co-receptors in CD4+ cells.
Entry Generic 
name
Experimental 
code
Company Molecule type Target Notes Ref. 
1 Plerixafor AMD3100 Small molecule CXCR4 Little antiviral activity 
shown in clinical trials
evolved into a 
stem cell-mobilizing 
agent. 
[29,31] 
2 KRH-1636 Kureha Chem Industry Small molecule CXCR4 [30]
3 TAK-779 
TAK-220
TAK-652 
Takeda Chemical Ind. Small molecule CCR5 TAK-779
currently not further 
developed. 
TAK-652 currently 
developed by Tobira 
Therapeutics as 
TBR-652.
[31,38,39,140] 
4 CMPD167 Merck Small molecule CCR5 [40,41]
5 Maraviroc UK-427,857 ViiV Healthcare
Pfizer
Small molecule CCR5 US FDA approved Aug 
2007
[42,43]
6 Vicriviroc SCH-D; 
SCH-417690
Schering-Plough 
Corporation
(now Merck)
Small molecule CCR5 Experimental
Phase II ongoing.
Possible association with 
increased risk for 
malignancies. 
[31,44,45] 
7 Aplaviroc GlaxoSmithKline Small molecule CCR5 Discontinued for liver 
toxicity.
[46]
8 PRO 140 Progenics 
Pharmaceuticals
Monoclonal
antibody
CCR5 Phase II trial concluded. [60]
9 Modified 
RANTES
(AOP-RANTES) 
Modification of 
RANTES, a 
CCR5-binding 
chemokine
CCR5 [59]
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2005 for dose-related liver toxicity problems. 
However, recent reports have concluded that co-
administration of aplaviroc with the immuno-
modulatory drug rapamycin, which is able to 
reduce CCR5 density (receptors/cell), enhances 
the antiviral activity of aplaviroc, allowing a 
reduction of active concentration to nontoxic 
doses (as much as 25-fold in vitro) and could 
provide an effective means to control infec-
tion [47]. Optimization of aplaviroc’s spirodiketo-
piperazine framework with improved pharmaco-
kinetic profiles has been reported very recently 
by Ono Pharmaceuticals [48].
Vicriviroc contains a piperazine scaffold 
(FiguRe 2) and was developed by Schering-
Plough starting from screening data; it exhibited 
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excellent selectivity for CCR5 receptors but clin-
ical trials were recently interrupted, at least for 
the treatment of naive patients [201]. 
Maraviroc is the only CCR5 inhibitor cur-
rently approved by the FDA (Selzentry). It is 
based on a tropane scaffold (FiguRe 2) and its 
development, starting from high-throughput 
screening (HTS) leads, has been reviewed else-
where [42,43]. The development and optimization 
of a new class of CCR5 antagonists replacing 
the tropane core of maraviroc by piperidine was 
recently described by Pfizer [49,50]. 
Other recent reports on the discovery and opti-
mization of novel CCR5 antagonists as inhibitors 
of HIV-1 infection have uncovered selective and 
potent analogs, which include structural elements 
from the previous chemotypes [51–54] or novel, 
gem-disubstituted azacycles and one octahydro 
pyrrolo[3,4-c]pyrrole scaffold [55]. The different 
CCR5 antagonists, despite being rather diverse 
in shape and electronic properties, are all pre-
dicted to bind to a putative hydrophobic binding 
pocket located in the transmembrane domain of 
the receptor [56–58].
Macromolecules capable of antagonizing 
CCR5 include modifications of its natural 
ligand, the CCR5 chemokine also known as 
RANTES [59]. Notably, RANTES is not the only 
natural ligand of CCR5, as other chemokines, 
including MIP-1a, MIP-1b (its variant LD78b) 
and MCP2 can bind this receptor. Monoclonal 
antibodies have also been developed that recog-
nize epitopes on CCR5 [60]. Their use in combi-
nation with small molecule antagonists has been 
recently reported as a promising new strategy for 
anti-HIV-1 therapy [61,62].
The success of some compounds such as maravi-
roc, approved by the FDA for clinical use, validates 
viral entry inhibitors as a new class of antiretroviral 
drugs for clinical use. However, some problems 
remain. The HIV envelope glyco protein is highly 
variable with diverse genotypes and, hence, the 
susceptibility of viral strains to different antago-
nists targeting the viral envelope glycoprotein may 
vary significantly. In addition, for the appropriate 
selection of treatment with co-receptor antago-
nists, HIV patients must initially be analyzed for 
the tropism of the virus they harbour. Moreover, 
because CCR5 and CXCR4 co-receptors are host 
cellular targets, the long-term effects and safety of 
drug use must also be closely monitored. 
With increasing knowledge of the HIV entry 
process, other targets involved in different stages 
of viral entry have emerged and will be discussed 
in the following sections. 
	n DC-SIGN inhibitors
A potential therapeutic target was recently 
identified in DC-SIGN, a receptor involved in 
the early stages of HIV infection [11]. DC-SIGN 
is a tetrameric calcium-dependent (C-type) lec-
tin, expressed by dendritic cells (DC), which 
specifically recognizes highly glycosylated struc-
tures displayed at the surface of several patho-
gens [63–66]. Recognition by DC-SIGN was 
reported to play a key role in HIV transmission 
and is considered an interesting new target for 
the design of anti-viral agents [67–71].
DC-SIGN+ immature DCs, located in vaginal, 
cervical and rectal mucosae are among the first 
cell types to encounter HIV during sexual trans-
mission. DC-SIGN expressed by DC at mucosal 
tissues captures HIV at low titre by binding the 
envelope glycoprotein gp120. The lectin appears 
to act as an attachment factor, rather than an 
entry receptor, binding and concentrating HIV 
on the cell surface. Initial reports described two 
different pathways that may be involved in the 
transmission of DC-SIGN-bound HIV to T lym-
phocytes [72,73]. The first one, responsible for short 
term HIV transfer (24 h after HIV exposure), 
involves virion internalization into intracellular 
compartments where the virus is protected from 
degradation and retains a high infective capacity 
during DC migration to lymphoid tissues (the 
‘Trojan horse model’) [74]. The second, involved 
in long-term HIV transfer (72 h after expo-
sure), follows DC infection in cis by transfer of 
DC-SIGN-bound virus to canonical HIV entry 
receptor (CD4 and CCR5) resulting in infected 
DC with a continuous production of virus for 
the T-cells [73,75]. In both cases, upon arrival at 
lymphoid tissues DC efficiently transmit HIV to 
CD4+ T lymphocytes, a process called infection 
in trans. These models have been challenged [76] 
and other reports have shown that the majority 
of virus internalized by DC is regularly processed 
by major histocompatibility complex presenta-
tion [77,78]. On the other hand, HIV sequestration 
by and stimulation of DC-SIGN was reported to 
help HIV evade immune responses and spread 
to cells by alternative pathways, such as the 
triggering of activities required for HIV replica-
tion [79] or induction of immunosuppressive sig-
nals[12–17].  A timely and comprehensive discus-
sion of the role of DC-SIGN in HIV infection 
has recently been published [80].
Despite uncertainties about the mechanism 
of action of this lectin, various groups are work-
ing to design molecules capable of blocking the 
interaction between DC-SIGN and HIV, with 
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the goal of disclosing a new strategy to prevent 
HIV transmission and infection of the host. A 
handful of compounds have been described so 
far (Tables 2 & 3). The main natural ligands rec-
ognized by the carbohydrate recognition domain 
of DC-SIGN are the high mannose glycan, 
(Man)
9
(GlcNAc)
2
 also known as Man
9
, and a 
group of fucosylated oligosaccharides bearing 
Lewis-type epitopes [74]. Highly mannosylated 
polyvalent compounds, structural analogues of 
Man
9 
terminal di- or trisaccharides, and mimics 
of the Lewis-× trisaccharide have been investi-
gated and found to be capable of antagonizing 
binding of gp120 to DC-SIGN. Although most 
of the work was concerned with mannose or 
mannose analogues, a fucose-based antagonist 
(6) was recently reported (entry 8; Table 2) [70]. 
The ligand is based on a a-fucosylamide anchor 
and inhibits DC-SIGN binding to mannosyl-
ated bovine serum albumin (BSA) with potency 
Table 2. Known monovalent ligands of dendritic cell-specific ICAM-3 grabbing nonintegrin. 
Entry Compound IC50 (mM) Inhibition (%) Assay Ref.
1
 
O
OH
HO
CH2OH
OH
HO
H2NH2C
2
0.35† SPR
(gp120 chip)
[69]
2 Mana-1,2-Mana-1,2-Man 73‡ Microarrays [141]
3 Mana-1,2-Mana-1,6-Mana-1,6-Man 73‡ Microarrays [141]
4
N
H
N
S
N
S
H
NN
Me
Me
Me
O
3
1.6 x 10-3§ Competition with
immobilized 
DC-SIGN
[68]
5
O
O
O
NH2
HO
HO
HO
OH
MeOOC
MeOOC
4
0.62¶ Ebola cis-infection
model
[67]
0.6#
1.0††
SPR (inhibition of
ManBSA binding)
[86]
6
O
O
HO
HO
HO
OH
MeOOC
MeOOC
O
O
HO
HO
OH
O
NH2
5
0.05#
0.125††
SPR (inhibition of
ManBSA binding)
[86]
7 Lewis-x trisaccharide 0.8#,‡‡ SPR (inhibition of
ManBSA binding)
[70]
8
O
OH
OH
Me OH
H
N
H
H
O
HN
O
COOMe
OH
HO
6
0.35#,‡‡ SPR (inhibition of
ManBSA binding)
[70]
†IC
50
 of mannose in the same assay 17 mM. 
‡100% is Man
9
 in the same assay. 
§IC
50
 of ManNAc in the same assay 6.9 mM. 
¶Mana-1,2-Mana-1-OCH
2
CH
2
NH
2
 is 1.9 mM in the same assay. 
#IC
50
 of mannose in the same assay 1.8 mM. 
††IC
50
 of mannose in the same assay 2.5 mM. 
‡‡IC
50
 of fucose in the same assay 1.2 mM.
DC-SIGN: Dendritic cell-specific ICAM-3 grabbing nonintegrin; Man: Mannose; ManBSA: Mannose bovine serum albumin; SPR: Surface plasmon resonance. 
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similar to, or slightly better than, the natural 
ligand’s Lewis-x. This molecule represents an 
interesting lead for further optimization. 
Multivalent presentation of mannose using 
hyperbranched dendritic polymers of Boltorn 
type were shown to bind DC-SIGN and inhibit 
interaction with gp120-coated surface plasmon 
resonance (SPR) chips (entry 1; Table 3) [81–83]. 
The Wong group reported oligo mannose 
dendrons that display complex oligo mannoses 
in high density (entries 2 & 3; Table 3) and 
inhibit binding of gp120 to recombinant 
dimeric DC-SIGN with IC
50
 in the nanomolar 
range [84]. These systems are excellent models of 
DC-SIGN inhibition, but their practical applica-
tion as therapeutic agents seems unlikely, given 
the complexity of the oligosaccharides used. 
Penadés, Alcami and their groups have reported 
that gold nanoparticles (GNP) displaying vari-
ous linear and branched mannosyl oligosaccha-
rides (Manno-GNPs, entries 4 & 5; Table 3) are 
potent inhibitors of DC-SIGN mediated HIV 
trans-infection of human activated peripheral 
blood mono-nuclear cells [85].  However, in vivo 
use of GNPs raises some concerns, mostly 
because of the potential toxicity produced by 
gold accumulation. 
Noncarbohydrate inhibitors with IC
50
 values 
in the low micromolar range, such as compound 
3 (entry 4; Table 2), were identified by Kiessling 
and Borrok via HTS of approximately 36,000 
compounds from commercial libraries [68]. 
Additional results from the Fleet group indicate 
that 2-C-substituted branched d-mannose ana-
logues such as compound 2 (entry 1; Table 2) 
bind to DC-SIGN with significantly greater 
affinity than mannose [69].  We have described 
two glycomimetic compounds, 4 and 5 (entries 
5 & 6 respectively; Table 2), which are struc-
tural mimics of linear di- and tri-mannosides 
and exhibit moderate anti-infective action 
against DC-SIGN-mediated infections by HIV 
and Ebola [67,86]. A tetravalent dendron con-
taining four copies of the linear trimannoside 
mimic 5 (entry 7; Table 3) was found to inhibit 
DC-SIGN mediated HIV trans-infection of 
CD4+ T lymphocytes at low micromolar range. 
The anti-infective action is exerted upstream of 
Table 3. Affinity comparison for polyvalent ligands of dendritic cell-specific ICAM-3 grabbing nonintegrin.
Entry Type of sugar Support Valency IC50 Rel.
Pot.
Assay Ref.
1 Man 3G Boltorn 
dendrimer
32 0.337 µM 118 Ebola cis-infection model [82]
0.1 µM SPR (high-density DC-SIGN ECD) [83]
50 µM SPR
gp120 chip
[81]
2 Man
4
(Mana-1,2-Mana-1,2-Mana-
1,3-Mana- R)
2G alkynyl 
dendrimer
9 0.020 µM† gp120 –Fc-DC-SIGN
ELISA
[84]
0.16 µM Competition with Man
4
-coated 
array
3 Man
9
2G alkynyl 
dendrimer
9 0.008 µM† gp120 –Fc-DC-SIGN
ELISA
[84]
0.026 µM Competition with Man
4
-coated 
array
4 Mana-1,2-Man GNP 22 2‡–37§ nM HIV trans-infection model [85]
25 0.12 µM
100% 
inhibition
2.9 SPR
gp120 chip
[141]
5 Man
4
(Mana-1,2-Mana-1,2-Mana-
1,3-Mana- R)
GNP 56 0.34‡–
0.83§ nM 
HIV trans-infection model [85]
6 Man Tetravalent
boltorn dendron 
4 50 µM HIV trans-infection model [86]
7 5 (mimic of Mana-1,2-
Mana-1,6-Mana)
Tetravalent
boltorn dendron 
4 5 µM HIV trans-infection model [86]
†Man is 8.5 mM in the same assay. 
‡JR-Renilla viral strain (R5). 
§NL-Renilla viral strain (X4).
DC-SIGN: Dendritic cell-specific ICAM-3 grabbing nonintegrin; ECD: Extracellular domain; GNP: Glyconanoparticle; Man: Mannose; SPR: Surface plasmon resonance. 
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cytokine involvement and, therefore, is indepen-
dent of viral tropism, as shown by inhibition of a 
series of laboratory-adapted strains and primary 
isolates with different tropism. This tetravalent 
compound presents high solubility in physiologi-
cal media, a neglectable cytotoxicity and a long-
lasting effect and was found to be stable for at 
least 1 week at pH 5 (an acidic medium close to 
that found at the vaginal mucosa, pH 4). Time-
course studies showed that the antiviral effect 
of this compound persists for hours, even after 
the B-THP/ DC-SIGN+ cells used were exposed 
to HIV after washing out the antagonist. The 
mechanism of this inhibition after removal 
may be based on the persistency of the multi-
valent ligand on the receptor binding site (slow 
off-rate of the tetravalent compound from the 
protein). However, flow cytometry studies sug-
gested that exposure of B-THP/DC-SIGN+ cells 
to this compound may also alter the observed 
cell surface concentration of DC-SIGN, possi-
bly by induced endocytosis. Depletion of recep-
tor membrane concentration is an interesting 
feature of this compound and it could at least 
partially account for its antiviral activity. 
Inhibition of DC-SIGN is not devoid of 
potential drawbacks. First and foremost, effi-
cient inhibition of this lectin will prevent recog-
nition of other pathogens besides HIV and, thus, 
may lead to a generalized reduction of the host 
immune response. This effect may be limited by 
topical, rather than systemic, use of inhibitors.
Virus targets
	n gp120 binders
Polyanions are one of the most popular groups 
of compounds to be formulated as microbi-
cides due to their low cost and easy produc-
tion. These compounds interact with the posi-
tively charged region of gp120, basically the 
conservative V3 loop, inhibiting the interaction 
with negative areas of the cell membrane sur-
face. Different formulations of these compounds 
have reached clinical Phase trials (Table 4). PRO 
2000/5 or PRO-2000, a formaldehyde-sodium 
2-naphthalene sulfonate polymer, was recently 
demonstrated to be ineffective in Phase III clini-
cal trials [24]. SPL7013, a lysine-based dendrimer 
with naphthalene disulfonic acid surface groups, 
also known as VivaGel™, is in Phase I/II clinical 
trials [87]. Dextrin sulfate (DxS) is also currently 
in clinical trials [88]. Some of these polyanions, in 
contrast to their very good  in vitro activity, have 
failed to demonstrate efficacy in preventing HIV 
transmission in Phase III clinical trials, as was 
the case of cellulose sulfate (CS), terminated pre-
maturely in early 2007 [89], and Carraguard [90]. 
Although some of these polyanion compounds 
enhance HIV infection, apparently this effect is 
not related to the nature of the polyanion, but 
to the assay conditions and therefore cannot 
be extrapolated [91]. 
CD4 is considered to be the main recep-
tor for the HIV-1. So, gp120-CD4 interaction 
has been one of the first targets against which 
anti-HIV drugs were developed. In 1990 it was 
reported that recombinant soluble CD4 (sCD4) 
protein was able to block HIV entry and subse-
quent infection in vitro [92]. However, Phase I/II 
clinical trials demonstrated that higher concen-
trations of this sCD4 were needed to inhibit 
infection in vivo using HIV primary isolates. 
Apparently, the binding of sCD4 to gp120 
should produce conformational changes on the 
gp120 envelope protein, leading to the expo-
sure of co-receptor binding sites. These changes 
could allow gp120 to bind the chemokine 
receptor at the cell surface, inducing virus–cell 
membrane fusion and virus entry [93]. This fact 
could explain the results found in the infection 
Table 4. Current status of polyanions as microbicides.
Compound Administration Composition Company Current status Ref.
PRO2000 Topical 0.5% gel Formaldehyde-sodium
2-naphthalenesulfonate
polymer
Indevus Pharmaceuticals Failed in Phase III
trials
[24]
SPL7013 VivaGel
(3% SPL7013 gel)
Lysine dendrimer with 
naphtalene disulfonic 
acids
Starpharma Phase I/II
trials
[87]
Carraguard Gel from carrageenan Sulfated polysaccharide Ineffective in 
Phase III trials
[90]
Dextrin sulfate Oral or intravenous 
administration Polysulfate dextran
Phase I/II
trials
[88]
Cellulose sulfate (Ushecell)
Topical 6% gel 
Polysulfate cellulose Polydex Pharmaceuticals Ineffective in 
Phase III trials
[89]
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experiments. A detailed mechanistic study of the 
binding process of sCD4 (or a mimic) to the 
gp120 was carried out. Moreover, it was pointed 
out that the conformational changes caused by 
binding could expose neutralization epitopes on 
gp120, which were responsible for eliciting the 
generation of neutralizing antibodies as part of 
a strategy to develop vaccines [94,95]. There are 
some concerns with this approach, most of them 
refering to the problem of eliciting antibodies 
against the CD4 molecule. Crosslinked gp120-
CD4 or similar strategies producing more stable 
complexes could avoid these problems. 
In this context, a new strategy to inhibit 
HIV entry was very recently developed. This 
strategy was based on a neoglycoconjugate 
(mCD4-HS
12
) that covalently combines a 
heparan sulfate dodeca saccharide (HS
12
) and 
a CD4 peptide mimic (mCD4; FiguRe 3) [96]. 
The peptide was synthesized according to a 
solid-phase approach and a maleimido group 
was introduced on the Lys-5 side chain for sugar 
conjugation. The heparan sulfate dodecamer 
was prepared with a sulfydryl moiety at the 
reducing end allowing the conjugation to the 
maleimido-activate peptide. This conjugate 
simultaneously targets in a co operative man-
ner two highly conserved domains of gp120 
that are critical for virus entry: the co-receptor 
and the CD4 binding sites. A clear synergis-
tic effect was observed in comparison with the 
activity presented by the isolated moieties of the 
glycoconjugate. The most interesting feature of 
the binding mode resides on the first binding 
event of the mCD4 peptide to gp120, exposing 
the co-receptor binding site and allowing, in a 
second step, binding of the sugar moiety [96]. 
mCD4-HS
12
 binds to gp120 in a 1:1 molar 
ratio with a dissociation constant in the low 
nanomolar range, as demonstrated using surface 
plasmon resonance. Moreover, infection stud-
ies on blood mono nuclear cells showed a dose-
dependent inhibition effect independently of 
the viral strain (R5, X4 or dual tropism R5/X4). 
The inhibition activity was shown to be based 
on the blockage of the virus envelope [96].
Neutralizing antibodies are very attractive 
owing to their potential application as entry 
inhibitors of HIV as well as their importance 
for the development of vaccines against this 
virus [97,98]. Several monoclonal antibodies have 
been characterized showing different activities 
and selectivities. Those that present moderate 
to strong potency with a broad spectrum of rec-
ognition are the b12 antibody (interacting with 
the CD4 binding site on gp120) [99], the 2G12 
antibody (which recognizes the carbohydrate 
epitope Mana1,2Man on gp120) [100] and 2F5 
antibody (which interacts with the membrane 
proximal region on gp41) [101]. Active research in 
this area is ongoing and may open the door for 
the design and production of more effective and 
broad antibodies with therapeutic applications 
in HIV infection [102,103].
Carbohydrate-binding proteins (CBPs) are 
one of the most classical sources of compounds 
that exhibit antiviral activity through the inter-
action with glycans presented on gp120. These 
lectins can be isolated from different species 
such as plants, cyanobacteria and algae, and 
have recently been reviewed elsewhere [104,105]. 
Two of these CBPs have been studied more 
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extensively: cyanovirin N (CV-N) from cya-
nobacteria [106] and griffithsin (GRFT) from 
Griffthsia sp algae [107]. 
Cyanovirin N has been tested in vivo as a topi-
cal gel for vaginal [108] and rectal [109] application 
in macaques using the chimera SHIV as infec-
tive agent. In these studies, relevant antiviral 
activity was found demonstrating a promising 
application as microbicide. The potent antiviral 
activity has recently been evaluated in cellular 
and cervical explant models using different 
primary HIV-1 clinical isolates. Ex vivo experi-
ments showed that CV-N was able to inhibit 
infection of cervical explants by HIV-1 (BaL 
strain) with an IC
90
 of 1 µM [110]. In addition, as 
preclinical evaluation, the antiviral activity was 
analyzed in the presence of semen, which pro-
duced a modest decrease in the antiviral activity 
of cyanovirin-N [110]. More significant were the 
safety concerns due to mitogenic properties of 
this lectin [111]. Low levels of T-cell proliferation 
were found after three days’ exposure of cells 
to CV-N. This fact should be studied in more 
detail for the potential topical application of 
CV-N as a microbicide. 
To date, GRFT isolated from marine red algae 
and characterized in 2005 is the most potent 
anti-HIV inhibitor described, with EC
50
 in the 
picomolar range [107]. The spectra of activity 
include HIV-1 clades A, B, and C. The mech-
anism of GRFT as an entry inhibitor centres 
on the binding, in a calcium-nondependent 
manner, to the sugars present on the envelope 
glycoprotein gp120, blocking the interaction 
of HIV to target cells. The high activity found 
for GRFT in comparison with other lectins 
such as CV-N has been explained based on the 
possibility of multivalent binding with gp120. 
This is possible because GRFT contains six 
carbohydrate-binding sites per homodimer. 
What makes this potential virucide especially 
interesting is the lack of toxicity and the extreme 
stability under a variety of physical conditions 
including low pH and temperatures up to 
80°C [111]. Despite the high antiviral activity 
showed by these protein inhibitors, clinical trials 
have not yet been carried out. The main draw-
backs of these potential drugs are the high pro-
duction cost and the accessibility of the amounts 
of material required to perform clinical studies. 
In the particular case of GRFT, this problem 
has been successfully addressed by the produc-
tion of recombinant GRFT produced in plants. 
The protein isolated from the plant (GRFT-P) 
showed the same antiviral activity as the natural 
protein. This approach allows the production of 
more than 1 g of protein (purity >99%) per kg 
of Nicotiana benthamiana leaf material, which 
is a very reasonable amount, suitable for clini-
cal test formulations as a microbicide [112]. As 
stated in this publication, this technology will 
provide the necessary production of GRFT to 
proceed into clinical tests. Furthermore, it was 
demonstrated that this lectin had no toxic effects 
in vitro and ex vivo human cervical explants, 
and has not induced inflammatory response 
in vaginal epithelial tissues, which indicates a 
safety profile adequate for their human applica-
tion. At this stage, griffithsin can be considered 
one of the most promising candidates for use 
as microbicide. 
In general terms, the availability, synthetic 
cost, stability and immunogenic effects associ-
ated with peptides or proteins as drugs for clini-
cal use, have led to the search for new strate-
gies to design new carbohydrate-binding agents 
(CBAs) with nonpeptidic structures. Kiser 
and co-workers have developed an approach 
based on a polymer bearing several copies of 
O-hydroxymethylphenylboronic acid (benzo-
boroxole; FiguRe 4) [113]. At physiological pH, 
benzoboroxole interacts with the hydroxyl 
groups of manno- and galactopyranosides, car-
bohydrate units abundantly present on viral 
glycoproteins such as gp120. In these studies, 
it was demonstrated that these polymers exhibit 
strong antiviral activity inhibiting the infection 
of peripheral blood mononuclear cells by HIV of 
two different clades (B and C) and two co-recep-
tor tropism (X4 and R5). The activity was related 
to the percentage of boronic acid present in the 
polymer, the most active being a polymer with 
a 75% functionalization (~ 450 benzoboroxoles) 
with an EC
50
 of 10 nM independently of the 
HIV strain used in the infection studies. These 
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polymers exhibit low toxicity in the vaginal cell 
line used, at least for the highest concentration 
tested (two orders of magnitude > EC
50
). The 
inhibition activity exhibited by these polymers 
are likely based on preventing binding of gp120 
to CD4, the co-receptor, or both but this point 
was not clarified. The spectrum activity and the 
efficacy is comparable with CV-N but with the 
advantage of a more economically scalable pro-
duction for application, which makes this com-
pound very promising as microbicide, although 
in vivo activity still needs to be tested.
Among nonpeptidic compounds, benzo-
napht acene quinone antibiotics pradimicin A 
(PRM-A) [114] and pradimicin S (PRM-S; 
FiguRe 5) [115] have a very interesting antivi-
ral activity through interaction, in a calcium-
dependent manner, with carbohydrates of the 
viral envelope glycoprotein gp120. PRMs were 
considered as CBA leads for HIV therapy with 
a novel therapeutic concept for a potential dual 
mechanism proposed for PRM derivatives. 
This dual mechanism consisted of a direct 
antiviral activity blocking HIV entry and a 
second action based on progressively inducing 
deletion of glycosylation sites on gp120, which 
induces neutralization through the activation of 
the immune system against previously hidden 
immunogenic epitopes. Their low toxicity, stabil-
ity and broad spectrum of activity against HIV-1 
(different clades), HIV-2 and SIV make these 
compounds good candidates for develop ment 
as microbicides.
In 2003, a small molecule based on a 
4-methoxy-7-azaindole derivative named 
BMS-378806 (FiguRe 6) was described as a viral 
entry inhibitor of HIV [116]. This molecule 
showed a broad spectrum of activity against 
several HIV-1 laboratory strains and clinical 
isolates of the B subtype with an average EC
50
 
of 40 nM [117]. For other virus subtypes, the 
antiviral activity of this compound decreases. 
This activity was independent of the HIV-1 co-
receptor used (R5, X4 or R5/X4). The activity of 
this molecule resides on the interaction with the 
CD4 binding pocket of the viral envelope gp120 
with a 1:1 stoichio metry. Initial toxicology test 
and pharmacokinetics assays demonstrated the 
potential application and the possibility to enter 
into clinical studies. Optimization of this mol-
ecule led to the identification of a 6-azaindole 
derivative BMS-488043 (FiguRe 6) [118]. This 
molecule has improved the pharmacokinetic 
profile of BMS-378806 but besides the oral bio-
availability, drug dissolution in the gastrointes-
tinal tract should be improved using additional 
formulation approaches.
BMS-378806, in combination with other 
inhibitors, CMPD167 (a CCR5 inhibitor) and 
the peptide C52L (a fusion inhibitor) acting 
at different stage of virus–cell attachment was 
tested in vitro and in vivo [40].  In this study, 
it was clearly demonstrated that the combina-
tion of the three compounds delivered vaginally 
protected macaques against infection by SHIV 
inoculated vaginally. This approach opens up 
the possibility  of combining different avail-
able inhibitors in a synergistic manner, as a very 
powerful strategy against HIV infection.
	n gp41 binders (fusion inhibitors)
Fusion inhibitors are a class of entry inhibi-
tors that interfere at some point with the heli-
cal regions domains (HR1 and 2) of gp41 
involved in the 6-helix bundle formation, a 
step needed for membrane fusion, the process 
that proceeds to cell penetration. This type of 
HIV entry inhibitor has been reviewed very 
recently [119]. The discovery of the mechanism 
of HIV membrane fusion has allowed the 
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design of potential inhibitors interfering with 
the protein–protein interactions that trigger 
the fusion step. Peptides interfering with this 
protein–protein interaction were envisaged as 
potential therapeutic compounds inhibiting 
HIV entry. T20 (enfuvirtide), a 36-mer pep-
tide, was the first generation of HIV fusion 
inhibitors. This peptide is, for the moment, 
the only one approved by the FDA (in 2003) 
for clinical use in the treatment of AIDS [120]. 
The appearance of resistant strains due to the 
application of enfuvirtide induced the develop-
ment of new generations of fusion inhibitors 
such as T1249, a 39-mer peptide with higher 
activity than T20; C52L, a sequence-modified 
version of T20; T1144, a 38-mer peptide effec-
tive against T20-resistant HIV strains; sifurvit-
ide, a 36-mer peptide with better activity than 
T20; C34, derived from the HR2 of gp41, all 
of which have inhibitory activities in the nano-
molar range [121,122]. New strategies were sug-
gested, including a combination of two or more 
peptide-fusion inhibitors looking for a synergic 
activity [122] or conjugation of cholesterol (as a 
lipid anchor on the cell membrane) to a peptide 
fusion inhibitor (C34-Chol), producing a con-
jugate which was 50-fold more potent than the 
corresponding peptide [123]. In all cases, the sta-
bility and production of these peptides in large 
quantities proved to be an important drawback 
of this approach. In this context, d-peptides 
constructed by d-amino acid were considered 
a very powerful strategy to avoid the stability 
problems affecting natural peptides [124]. In 
fact, a relevant example of the potent activity 
exhibited by these peptides has recently been 
reported with a d-peptide exhibiting an EC
50
 
of 250 pM [125]. 
As a different approach for searching fusion 
inhibitors, nonpeptidic small molecules were 
considered. Natural triterpenes derivatives 
based on betulinic acid (BA; FiguRe 7) were 
described some time ago as potent antiviral 
compounds inhibiting HIV infection at an 
early stage of the infectious cycle, during the 
membrane fusion step [126]. These compounds 
were the f irst described with nonpeptidic 
nature that presented this activity. It has been 
reported that modification of the side chains 
can modulate the activity and the mechanism 
of action. Even more, depending on where 
these side chains (R
1
, R
2
 and R
3
) are placed, 
the mechanism of action can change and the 
compounds can act as entry inhibitors or as 
a maturation inhibitors (FiguRe 7) [127]. One 
interesting example is bevirimat (FiguRe 7) , 
currently in Phase IIb clinical trials launched 
by Panacos Pharmaceuticals, Inc. and now 
developed by Myriad Genetics as a maturation 
inhibitor [128]. Compounds with no substitu-
tion in position C3 (R
3
= H) interact with the 
V3 loop of HIV-1 inhibiting chemokine recep-
tor binding. It seems that this inhibition stops 
the required conformational changes in gp41 
needed for membrane  fusion.
Betulinic acid derivates exhibit a broad spec-
trum of activity against several HIV-1 laboratory 
strains and clinical isolates. Unfortunately, the 
clinical development of one of these derivatives 
(RPR 103611) by a pharmaceutical company was 
dropped because pharmacodynamic properties 
were found to be inadequate. Very recently, Lee 
and co-workers completed the synthesis of a 
large series of different BA derivatives with the 
aim of improving their properties and analyzing 
the effect of substituents on the inhibitory activ-
ity [129]. One of these compounds showed  good 
solubility and the same range of activity as the 
previous best hit A43-D.
N-carboxyphenylpyrrole derivatives were 
found to be very promising molecules target-
ing gp41 [130]. In a hit-to-lead optimization 
 
R3O
H
H
H
H
N
R2
R1
O
H
 
      
O
H
H
H
OH
O
H
  
N
H
CO2H
OH
O
HO
H
H
H
OH
O
H
 
HO
O
OBA
Bevirimat
RPR 103611: R1= H; R3=H; R2= (CH2)7
A43-D: R1= H; R2= (CH2)7-NH-CO-CH3; R3= H
BA derivatives
Figure 7. Betulinic acid and derivatives showing antiviral activity.
BA: Betulinic acid. 
Review | Reina, Bernardi, Clerici & Rojo
Future Med. Chem. (2010) 2(7)1154 future science group
process, a molecule indicated as A12 (FiguRe 8) 
was selected as the best inhibitor able to inhibit 
the gp41 6-helical bundle formation, with an 
EC
50
 of 37.36 µM [131]. Using A12 as a starting 
point, a more potent candidate, GLS-22, was 
obtained using a computer-aided de novo drug-
design methodology based on GeometryFit. 
This new N-carboxyphenylpyrrole derivative 
showed better activity (sixfold better than A12) 
as fusion inhibitor in HIV replication assay, low 
cytotoxicity (CC
50
: 227–355 µM) and the high-
est selectivity index (CC
50
/IC
50
: 51.99) [132]. 
Very recently, a study to identify com-
pounds as frequent hitters in biological 
high-throughput screens has been published. 
In this study, the structure of the A12 type 
compounds is described as one of the prob-
lematic leads, leading to questions regarding 
their applicability [133].
Another type of small molecule was identi-
fied as a nonpeptide entry inhibitor by NMR 
and docking experiments using a model of 
gp41 protein (Protein-1). From these studies, 
a series of molecules was selected, the best of 
which was 7 (FiguRe 9) with an EC
50
 of 3 µM 
in a cell–cell fusion assay in vitro [134]. This 
value is in the same order of magnitude as the 
activity obtained with d-peptides, but still far 
from that of the C-peptide (EC
50
: 4 nM). It is 
clear that this compound could be a potential 
hit for optimization.
Conclusion & future perspective
In the continuing absence of an effective vac-
cine, the use of a topical microbicide represents 
a credible alternative method for reducing the 
sexual transmission of HIV. However, so far, 
no compounds have been shown to prevent 
HIV transmission in efficacy trials. One cur-
rently emerging response to the failure of first-
generation candidates is the use of multiple 
microbicides to block the different mechanisms 
of HIV transmission [40,47,61,62,135,136]. The com-
bination of microbicides with complementary 
mechanisms of action is expected to increase 
the potency of the formulation and to be one 
possible answer to the problems posed by HIV-1 
diversity. Indeed, the combinations reported so 
far were all found to display synergistic activ-
ity in infection assays, so that, at lower concen-
trations, double and triple combinations were 
generally more effective than individual inhibi-
tors [40,137,138]. The chances of a virus being 
simultaneously resistant to three compounds 
is less than to any single inhibitor, a principle 
well established from clinical experience with 
drug-based therapies for HIV-1 infection [139]. 
In addition, drug combination could decrease 
the risk of selection of antiretroviral drug-
resistant strains and, finally, the combination 
of CXCR4- and CCR5-specific inhibitors may 
be useful for countering the transmission of 
dual-tropic viruses. 
The spread of HIV infection will not slow 
down and, if anything, will accelerate. Actual 
therapeutic approaches to HIV infection are 
highly effective. These therapies, nevertheless, 
are life-long and are associated with potentially 
life-threatening side effects. Additionally, the 
economic burden of treatment for HIV infec-
tion occupies an increasing share of healthcare 
expenditure, making current practices likely to 
become hard to sustain in the long run. The 
need for effective ways to prevent HIV infection 
and the difficulties in designing an effective 
vaccine will drive a strong worldwide effort to 
develop effective microbicides. It is likely that 
glycans/lectins (compounds that are easy to 
make, economic and easy to store) will emerge 
as the best candidates. In 10 years from now, we 
will probably not have an effective vaccine, but 
we might have very strong and positive results 
from Phase III trials based on the prevention 
of HIV transmission using glycans/lectins or 
CCR5 inhibitor-based microbicides.
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Executive summary
	n HIV infection is still highly incident; no effective vaccine is foreseeable in the near future.
	n HIV infection can be controlled but not cured by therapy, thus, prevention is indispensable.
	n Mucosal HIV infection is a complex, multistep process that can be prevented by the use of condoms. Ethical and cultural problems can 
reduce the use of condoms.
	n Microbicides capable of preventing HIV infection would have a major impact on the spread of disease; various compounds have been 
tested in vitro and/or in vivo, but so far, no effective compound has emerged.
	n HIV entry inhibitors, targeting glycans/lectins, CD4, CCR5, or the ‘fusion peptide’ are highly attractive candidates for preventing mucosally 
transmitted HIV infection.
	n A combination of microbicides targeting different steps of viral entry shows a synergistic effect and may result in more effective therapies 
and formulations.
	n Effective microbicides must be safe and nontoxic; devoid of inflammatory activity; resistant to seminal fluid low pH and body temperature; 
easy and simple to use (e.g., nonoily and nonleaking); economical; simple to produce and store and endowed with durable activity.
	n Effective microbicides must be able to protect against both receptive anal and vaginal intercourses.
Bibliography
Papers of special note have been highlighted as:
n  of interest
1 Buchbinder SP, Mehrotra DV, Duerr A et al. 
Efficacy assessment of a cell-mediated 
immunity HIV-1 vaccine (the step study): 
a double-blind, randomised, placebo-
controlled, test-of-concept trial. Lancet 
372(9653), 1881–1893 (2008).
n	 Rationally designed vaccine, which 
unfortunately and unexpectedly, turned out 
not to be effective.
2 Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S 
et al. Vaccination with ALVAC and AIDSVAX 
to prevent HIV-1 infection in Thailand. New 
Engl. J. Med. 361(23), 2209–2220 (2009). 
n	 A first, dim ray of hope in HIV vaccinology.
3 Balzarini J, Van Damme L. Microbicide drug 
candidates to prevent HIV infection. Lancet 
369(9563), 787–797 (2007).
4 Cutler B, Justman J. Vaginal microbicides and 
the prevention of HIV transmission. Lancet 
Infect. Dis. 8(11), 685–697 (2008).
5 Klasse PJ, Shattock R, Moore JP. 
Antiretroviral drug-based microbicides to 
prevent HIV-1 sexual transmission. Annu. Rev. 
Med. 59, 455–471 (2008). 
6 Grant RM, Hamer D, Hope T et al. Whither 
or wither microbicides? Science 321(5888), 
532–534 (2008).
7 Buckeit RW Jr, Watson KM, Morrow KM, 
Ham AS. Development of topical microbicides 
to prevent the sexual transmission of HIV. 
Antiviral Res. 85(1), 142–158 (2010).
8 Klasse PJ, Shattock RJ, Moore JP. Which 
topical microbicides for blocking HIV-1 
transmission will work in the real world? PLoS 
Med. 3(9), e351 (2006).
9 van de Wijgert JH, Shattock RJ. Vaginal 
microbicides: moving ahead after an 
unexpected setback. AIDS 21(18), 2369–2376 
(2007).
10 McGowan I. Microbicides for HIV prevention: 
reality or hope? Curr. Opin. Infect. Dis. 23(1), 
26–31 (2010).
11 Geijtenbeek TBH, Kwon DS, Torensma R et al. 
DC-SIGN, a dendritic cell-specific HIV-1-
binding protein that enhances trans-infection of 
T cells. Cell 100(5), 587–597 (2000).
n	 Established for the first time the role of 
dendritic cell membrane lectin, specific 
ICAM-3 grabbing nonintegrin (DC-SIGN) in 
transmission of HIV infection.
12 Shan M, Klasse PJ, Banerjee K et al. HIV-1 
gp120 mannose induce immunosupresive 
responses from dendritic cells. PLoS Pathogens 
3(11), e169 (2007).
13 van Kooyk Y. C-type lectins on dendritic 
cells: key modulators for the induction of 
immune responses. Biochem. Soc. Trans. 
36(6), 1478–1481 (2008).
14 den Dunnen J, Gringhuis SI, 
Geijtenbeek TBH. Innate signaling by the 
C-type lectin DC-SIGN dictates immune 
responses. Cancer Immunol. Immunother. 
58(7), 1149–1157 (2009).
15 Geijtenbeek TBH, den Dunnen J, 
Gringhuis SI. Pathogen recognition by 
DC-SIGN shapes adaptive immunity. Future 
Microbiol. 4(7), 879–890 (2009).
16 Gringhuis SI, den Dunnen J, Litjens M, 
van der Vlist M, Geijtenbeek TBH. 
Carbohydrate-specific signaling through the 
DC-SIGN signalosome tailors immunity to 
Mycobacterium tuberculosis, HIV-1 and 
Helicobacter pylori. Nat. Immunol. 10(10), 
1081–1089 (2010).
17 den Dunnen J, Gringhuis SI, 
Geijtenbeek TBH. Dusting the sugar 
fingerprint: C-type lectin signaling in 
adaptive immunity. Immunol. Lett. 128(1), 
12–16 (2010).
18 Ugoli S, Mondor I, Sattentau QJ. HIV-1 
attachment: another look. Trends Microbiol. 
7(4), 144–149 (1999).
19 Pöhlmann S, Doms RW. Evaluation of 
current approaches to inhibit HIV entry. 
Curr. Drug Targ. Infect. Disor. 2(1), 9–16 
(2002).
20 McKnight A, Weiss RA. Blocking the 
docking of HIV-1. Proc. Natl Acad. Sci. USA 
100(19), 10581–10582 (2003). 
Financial & competing interests disclosure
The authors thank the following grants for support: Azioni 
Integrate Italia-Spagna (IT074ABCCM and HI2005–
0212); the Ministry of Science and Innovation (MICINN, 
CTQ2008-01694); the FIRB program CHEM-
PROFARMANET (RBPR05NWWC); Marie Curie ITN 
FP7 project CARMUSYS (PITN-GA-2008–213592); 
Istituto Superiore di Sanita’ ‘Programma Nazionale di Ricerca 
sull’ AIDS’; the EMPRO and AVIP EC WP6 Projects; the 
nGIN EC WP7 Project; the Japan Health Science Foundation; 
2008 Ricerca Finalizzata [Italian Ministry of Health] and 
2008 Ricerca Corrente [Italian Ministry of Health]. The 
authors have no other relevant affiliations or financial involve-
ment with any organization or entity with a financial interest 
in or financial conflict with the subject matter or materials 
discussed in the manuscript, apart from those disclosed.
No writing assistance was utilized in the production of 
this manuscript. 
Review | Reina, Bernardi, Clerici & Rojo
Future Med. Chem. (2010) 2(7)1156 future science group
21 Esté JA, Telenti A. HIV entry inhibitors. 
Lancet 370(9581), 81–88 (2007).
22 Qian K, Morris-Natschke SL, Lee K-H. HIV 
entry inhibitors and their potential in HIV 
therapy. Med. Res. Rev. 29(2), 369–393 
(2009). 
23 Kuritzkes DR. HIV-1 entry inhibitors: an 
overview. Curr. Opin. HIV AIDS 4(2), 
82–87 (2009).
24 Chisembele M, Crook A, Gafos M et al. 
PRO2000 is ineffective in preventing HIV 
infection: results of the MDP301 Phase III 
Microbicide trial (Abstract 87LB). Presented 
at: CROI. San Francisco, CA, USA, 16–19 
February 2010. 
25 Moore JP, Sattentau QJ, Klasse PJ, 
Burkly LC. A monoclonal antibody to CD4 
domain 2 blocks soluble CD4-induced 
conformational changes in the envelope 
glycoproteins of human immunodeficiency 
virus type 1 (HIV-1) and HIV-1 infection of 
CD4+ cells. J. Virol. 66(8), 4784–4793 
(1992). 
26 Kuritzkes DR, Jacobson J, Powderly 
WG et al. Antiretroviral activity of the 
anti-CD4 monoclonal antibody TNX-355 in 
patients infected with HIV type 1. J. Infect. 
Dis. 189(2), 286–291 (2004). 
n	 Important proof of concept.
27 Ji C, Kopetzki E, Jekle A et al. 
CD4- anchoring HIV-1 fusion inhibitor with 
enhanced potency and in vivo stability. 
J. Biol. Chem. 284(8), 5175–5185 (2009).
28 Ford SL, Reddy YS, Anderson MT et al. 
Single-dose safety and pharmacokinetics of 
brecanavir, a novel human 
immunodeficiency virus protease inhibitor. 
Antimicrob. Agents Chemother. 50(6), 
2201–2206 (2006).
29 Donzella GA, Schols D, Lin SW et al. 
AMD3100, a small molecule inhibitor of 
HIV-1 entry via the CXCR4 co-receptor. 
Nat. Med. 4(1), 72–77 (1998). 
30 Ichiyama K, Yokoyama-Kumakura S, 
Tanaka Y et al. A duodenally absorbable 
CXC chemokine receptor 4 antagonist, 
KRH-1636, exhibits a potent and selective 
anti-HIV-1 activity Proc. Natl Acad. Sci. 
USA 100(7), 4185–4190 (2003).
31 De Clercq E. Antiviral drug discovery: ten 
more compounds, and ten more stories 
(Part B). Med. Res. Rev. 29(4), 571–610 
(2009).
32 Khan A, Nicholson G, Greenman J et al. 
Binding optimization through coordination 
chemistry: CXCR4 chemokine receptor 
antagonists from ultrarigid metal complexes. 
J. Am. Chem. Soc. 131(10), 3416–3417 
(2009).
33 Skerlj RT, Bridger GJ, Kaller A et al. 
Discovery of novel small molecule orally 
bioavailable C-X-C chemokine receptor 4 
antagonists that are potent inhibitors of 
T-tropic (X4) HIV-1 replication. J. Med. 
Chem. 53(8), 3376–3388 (2010).
34 Gudmundsson KS, Sebahar PR, 
Richardson LD et al. Amine substituted 
N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-
tetrahydro-8-quinolinamines as CXCR4 
antagonists with potent activity against 
HIV-1. Bioorg. Med. Chem. Lett. 19(17), 
5048–5052 (2009).
35 Maeda K, Nakata H, Ogata H et al. 
The current status of, and challenges in, the 
development of CCR5 inhibitors as 
therapeutics for HIV-1 infection. Curr. Opin. 
Pharmacol. 4(5), 447–452 (2004).
36 Wang T, Duan Y. HIV co-receptor CCR5: 
structure and interactions with inhibitors. 
Infect. Disord. Drug Targets 9(3), 279–288 
(2009).
37 Pulley SR. CCR5 antagonists: from discovery 
to clinical efficacy. In: Chemokine Biology - 
Basic Research and Clinical Application 
(Volume. 2). Kuldeep N, Gordon LL, 
Bernhard M (Eds.). Birkhauser Basel, 
Switzerland, 145–163 (2007).
38 Baba M, Nishimura O, Kanzaki N et al. 
A small-molecule, nonpeptide CCR5 
antagonist with highly potent and selective 
anti-HIV-1 activity. Proc. Natl Acad. Sci. USA 
96(10), 5698–5703 (1999). 
n	 Article that opens the road to the 
development of CCR5 inhibitors.
39 Dragic T, Trkola A, Thompson DA et al. 
A binding pocket for a small molecule 
inhibitor of HIV-1 entry within the 
transmembrane helices of CCR5. Proc. Natl 
Acad. Sci. USA 97(10), 5639–5644 (2000).
n	 Basis allowing the development of 
CCR5 inhibitors.
40 Veazey RS, Klasse PJ, Schader SM et al. 
Protection of macaques from vaginal SHIV 
challenge by vaginally delivered inhibitors of 
virus-cell fusion. Nature 438(3), 99–102 
(2005). 
41 Schröder C, Pierson RN, Nguyen B-NH et al. 
CCR5 blockade modulates inflammation and 
alloimmunity in primates. J. Immunol. 
179(4), 2289–2299 (2007).
42 Wood A, Armour D. The discovery of the 
CCR5 receptor antagonist, UK-427,857, a 
new agent for the treatment of HIV infection 
and AIDS. Prog. Med. Chem. 43, 239–271 
(2005). 
n	 Describes the discovery of the only CCR5 
antagonist currently approved by 
the US FDA.
43 Sayana S, Khanlou H. Maraviroc: a new 
CCR5 antagonist. Expert Rev. Anti Infect. 
Ther. 7(1), 9–19 (2009). 
44 Taga JR, Steensma RW, McCombie 
SW et al. Piperazine-based CCR5 
antagonists as HIV-1 inhibitors. II. 
Discovery of 1-[(2,4-dimethyl-3-pyridinyl)
carbonyl]-4- methyl-4-[3(S)-methyl-4-
[1(S)-[4-(trifluoro-methyl)phenyl]
ethyl]-1-piperazinyl]- piperidine N1-oxide 
(Sch-350634), an orally bioavailable, potent 
CCR5 antagonist. J. Med. Chem. 44(21), 
3343–3346 (2001). 
45 Strizki JM. Tremblay C, Xu S et al. 
Discovery and characterization of vicriviroc 
(SCH 417690), a CCR5 antagonist with 
potent activity against human 
immunodeficiency virus type 1. Antimicrob. 
Agents Chemother. 49(12), 4911–4919 
(2005). 
46 Maeda K, Nakata H, Koh Y et al. 
Spirodiketopiperazine-based CCR5 inhibitor 
which preserves CC-chemokine/CCR5 
interactions and exerts potent activity 
against R5 human immunodeficiency virus 
type 1 in vitro. J. Virol. 78(16), 8654–8662 
(2004). 
47 Latinovic O, Heredia A, Gallo RC, Reitz M, 
Le N, Redfield RR. Rapamycin enhances 
aplaviroc anti-HIV activity: implications for 
the clinical development of novel CCR5 
antagonists. Antiviral Res. 83(1), 86–89 
(2009).
48 Nishizawa R, Nishiyama T, Hisaichi K et al. 
Spirodiketopiperazine-based CCR5 
antagonists: improvement of their 
pharmacokinetic profiles. Bioorg. Med. 
Chem. Lett. 20(2), 763–766 (2010).
49 Barber CG, Blakemore DC, Chiva J-Y, 
Eastwood RL, Middleton DS, 
Paradowski KA. 1-amido-1-phenyl-3-
piperidinylbutanes – CCR5 antagonists for 
the treatment of HIV: Part 1. Bioorg. Med. 
Chem. Lett. 19(4), 1075–1079 (2009). 
50 Barber CG, Blakemore DC, Chiva J-Y, 
Eastwood RL, Middleton DS, 
Paradowski KA. 1-amido-1-phenyl-3-
piperidinylbutanes - CCR5 antagonists for 
the treatment of HIV: Part 2. Bioorg. Med. 
Chem. Lett. 19(5), 1499–1503 (2009). 
51 Pryde DC, Corless M, Fenwick DR et al. 
The design and discovery of novel amide 
CCR5 antagonists. Bioorg. Med. Chem. Lett. 
19(4), 1084–1088 (2009). 
52 Duan M, Aquino C, Ferris R et al. 
[2-(4-phenyl-4-piperidinyl)ethyl]amine 
based CCR5 antagonists: derivatizations at 
the N-terminal of the piperidine ring. 
Bioorg. Med. Chem. Lett., 19(6), 1610–1613 
(2009). 
HIV microbicides: state-of-the-art & new perspectives on the development of entry inhibitors | Review
www.future-science.com 1157future science group
53 Duan M, Aquino C, Dorsey GF, Ferris R, 
Kazmierski WM. 4,4-disubstituted 
cyclohexylamine based CCR5 chemokine 
receptor antagonists as anti-HIV-1 agents. 
Bioorg. Med. Chem. Lett. 19(17), 4988–4992 
(2009). 
54 Rotstein DM, Gabriel SD, Makra F et al. 
Spiropiperidine CCR5 antagonists. Bioorg. 
Med. Chem. Lett. 19(18), 5401–5406 
(2009). 
55 Lemoine RC, Petersen AC, Setti L et al. 
Evaluation of secondary amide replacements 
in a series of CCR5 antagonists as a means 
to increase intrinsic membrane permeability. 
Part 1: optimization of gem-disubstituted 
azacycles. Bioorg. Med. Chem. Lett. 20(2), 
704–708 (2010).
56 Maeda K, Das D, Ogata-Aoki H et al. 
Structural and molecular interactions of 
CCR5 inhibitors with CCR5. J. Biol. Chem. 
281(18), 12688–12698 (2006).
n	 First comprehensive structural 
interpretation of the activity of 
CCR5 antagonists.
57 Kondru R, Zhang J, Ji C et al. Molecular 
interactions of CCR5 with major classes of 
small-molecule anti-HIV CCR5 antagonists. 
Mol. Pharmacol. 73(3), 789–800 (2008).
58 Wang T, Duan Y. Binding modes of 
CCR5-targeting HIV entry inhibitors: 
partial and full antagonists. J. Mol. Graph. 
Model. 26(8), 287–295 (2008).
59 Hartley O, Gaertner H, Wilken J et al. 
Medicinal chemistry applied to a synthetic 
protein: development of highly potent HIV 
entry inhibitors. Proc. Natl Acad. Sci. USA 
101(47), 16460–16465 (2004).
60 Trkola A, Ketas TJ, Nagashima KA et al. 
Potent, broad-spectrum inhibition of human 
immunodeficiency virus type 1 by the CCR5 
monoclonal antibody PRO 140. J. Virol. 
75(2), 579–588 (2001). 
61 Murga JD, Franti M, Pevear DC et al. 
Potent antiviral synergy between 
monoclonal antibody and small-molecule 
CCR5 inhibitors of human 
immunodeficiency virus type 1. Antimicrob. 
Agents Chemother. 50(10), 3289–3296 
(2006). 
62 Ji C, Zhang J, Dioszegi M et al. CCR5 
Small-molecule antagonists and monoclonal 
antibodies exert potent synergistic antiviral 
effects by cobinding to the receptor. Mol. 
Pharmacol. 72(1), 18–28 (2007).
63 Geijtenbeek TBH, Torensma R, Van Vliet 
SJ et al. Identification of DC-SIGN, a novel 
dendritic cell-specific ICAM-3 receptor that 
supports primary immune responses. Cell 
100(5), 575–585 (2000).
64 Feinberg H, Mitchell DA, Drickamer K, 
Weis W. Structural basis for selective 
recognition of oligosaccharides by  
DC-SIGN and DC-SIGNR. Science 
294(5549), 2163–2166 (2001). 
n	 Describes the high-resolution x-ray structures 
of DC-SIGN complexes with both fucosylated 
and mannosylated oligosaccharides.
65 Mitchell DA, Fadden AJ, Drickamer K. A novel 
mechanism of carbohydrate recognition by the 
C-type Lectins DC-SIGN and DC-SIGNR. 
J. Biol. Chem. 276(31), 28939–28945 (2001).
66 van Kooyk Y, Geijtenbeek TBH. DC-SIGN: 
escape mechanism for pathogens. Nat. Rev. 
Immunol. 3(9), 697–709 (2003).
67 Reina JJ, Sattin S, Invernizzi D et al. 
1,2-mannobioside mimic: synthesis, DC-SIGN 
interaction by NMR and docking, and antiviral 
activity. ChemMedChem 2(7), 1030–1036 
(2007). 
68 Borrok MJ, Kiessling LL. Non-carbohydrate 
inhibitors of the lectin DC-SIGN. J. Am. 
Chem. Soc. 129(42), 12780–12785 (2007).
69 Mitchell DA, Jones NA, Hunter SJ et al. 
Synthesis of 2-C-branched derivatives of 
d-mannose: 2-C-aminomethyl-d-mannose 
binds to the human C-type lectin DC-SIGN 
with affinity greater than an order of 
magnitude compared with that of d-mannose. 
Tetrahedron: Asymmetry 18(12), 1502–1510 
(2007).
70 Timpano G, Tabarani G, Anderluh M et al. 
Synthesis of novel DC-SIGN ligands with an 
a-fucosylamide anchor. ChemBioChem 9(12), 
1921–1930 (2008).
71 Ernst B, Magnani JL. From carbohydrate leads 
to glycomimetic drugs. Nat. Rev. Drug 
Discovery 8(8), 661–677 (2009).
72 Turville SG, Santos JJ, Frank I et al. 
Immunodeficiency virus uptake, turnover, and 
2-phase transfer in human dendritic cells. Blood 
103(6), 2170–2179 (2004).
73 de Witte L, Nabatov A, Geijtenbeek TBH. 
Distinct roles for DC-SIGN+-dendritic cells 
and langerhans cells in HIV-1 transmission. 
Trends Mol. Med. 14(1), 12–19 (2008).
74 Kwon DS, Gregorio G, Bitton N et al. 
DC-SIGN-mediated internalization of HIV is 
required for trans-enhancement of T cell 
infection. Immunity 16(1), 135–144 (2002).
n	 Important work that clarifies the role of 
DC-SIGN in HIV infection.
75 Burleigh L, Lozach P-Y, Schiffer C et al. 
Infection of dendritic cells (DCs), not 
DC-SIGN-mediated internalization of human 
immunodeficiency virus, is required for 
long-term transfer of virus to T cells. J. Virol. 
80(6), 2949–2957 (2006).
n	 Clarifies the role of DC-SIGN in 
HIV infection.
76 Boggiano C, Manel N, Littman DR. Dendritic 
cell-mediated trans-enhancement of human 
immunodeficiency virus type 1 infectivity is 
independent of DC-SIGN. J. Virol. 81(5), 
2519–2523 (2007).
77 Moris A, Nobile C, Buseyne F, Porrot F, 
Abastado JP, Schwartz O. DC-SIGN promotes 
exogenous MHC-I-restricted HIV-1 antigen 
presentation. Blood 103(7), 2648–2654 (2004). 
78 Moris A, Pajot A, Blanchet F, 
Guivel-Benhassine F, Salcedo M, Schwartz O. 
Dendritic cells and HIV-specific CD4+ T cells: 
HIV antigen presentation, T-cell activation, 
and viral transfer. Blood 108(5), 
1643–1651(2006).
79 Hodges A, Sharrocks K, Edelmann M et al. 
Activation of the lectin DC-SIGN induces an 
immature dendritic cell phenotype triggering 
Rho-GTPase activity required for HIV-1 
replication. Nat. Immunol. 8(6), 569–577 
(2007).
80 Steffen I, Tsegaye TS, Poehlmann S. 
Lectin-like interactions in virus-cell 
recognition: human immunodeficiency virus 
and C-type lectin interactions. In: Microbial 
Glycobiology, Structures, Relevance and 
Applications. Moran A, Holst O, Brennan P, 
von Itzstein M (Eds). Elsevier, NY, USA, 
567–584 (2009).
81 Tabarani G, Reina JJ, Ebel C et al. Mannose 
hyperbranched dendritic polymers interact 
with clustered organization of DC-SIGN and 
inhibit gp120 binding. FEBS Lett. 580(10), 
2402–2408 (2006).
82 Rojo J, Delgado R. Glycodendritic structures: 
promising new antiviral drugs. J. Antimicrob. 
Chemother. 54(3), 579–581 (2004). 
83 Lasala F, Arce E, Otero JR et al. Mannosyl 
glycodendritic structure inhibits DC-SIGN-
mediated Ebola virus infection in cis and in 
trans. Antimicrob. Agents Chemother. 47(12), 
3970–3972 (2003). 
84 Wang S-K, Liang P-H, Astronomo RD et al. 
Targeting the carbohydrates on HIV-1: 
interaction of oligomannose dendrons with 
human monoclonal antibody 2G12 and 
DC-SIGN. Proc. Natl Acad. Sci. USA 105(10), 
3690–3695 (2008).
85 Martinez-Avila O, Bedoya LM, Marradi M 
et al. Multivalent manno-glyconanoparticles 
inhibit DC-SIGN-mediated HIV-1 trans-
infection of human T cells. ChemBioChem 
10(11), 1806–1809 (2009).
86 Sattin S, Daghetti A, Thépaut M et al. 
Inhibition of DC-SIGN-mediated HIV 
infection by a linear trimannoside mimic in a 
tetravalent presentation. ACS Chem. Biol. 5(3), 
301–312 (2010).
Review | Reina, Bernardi, Clerici & Rojo
Future Med. Chem. (2010) 2(7)1158 future science group
87 O’Loughlin J, Millwood IY, McDonald HM, 
Price CF, Kaldor JM, Paull JR. Safety, 
tolerability, and pharmacokinetics of 
SPL7013 gel (VivaGel): a dose ranging, Phase 
I study. Sex. Transm. Dis. 37(2),100–104 
(2010).
88 Fletcher PS, Wallace GS, Mesquita PMM, 
Shattock RJ. Candidate polyanion 
microbicides inhibit HIV-1 infection and 
dissemination pathways in human cervical 
explants. Retrovirology 3, 46 (2006).
89 Van Damme L, Govinden R, 
Mirembe FM et al. Lack of effectiveness of 
cellulose 21 sulfate gel for the prevention of 
vaginal HIV transmission. N. Engl. J. Med. 
359(5), 463–472 (2008).
n	 Disappointing results of a well-conducted 
clinical trial.
90 Skoler-Karpoff S, Ramjee G, Ahmed K et al. 
Efficacy of Carraguard for prevention of HIV 
infection in women in South Africa: a 
randomized, double-blind, placebo-controlled 
trial. Lancet 372(9654), 1977–1987 (2008).
n	 First report to suggest possible efficacy of 
microbicides in preventing HIV infection.
91 Sonza S, Johnson A, Tyssen D et al.  
Enhancement of human immunodeficiency 
virus type 1 replication is not intrinsic to all 
polyanion-based microbicides. Antimicrob. 
Agents Chemother. 53(8), 3565–3568 (2009). 
92 Daar ES, Li XL, Moudgil T, Ho DD. High 
concentrations of recombinant soluble CD4 
are required to neutralized primary 
immunodeficiency virus type 1 isolates. Proc. 
Natl Acad. Sci. USA 87(17), 6574–6578 
(1990).
93 Haim H, Si Z, Madani N et al. Soluble CD4 
and CD4-mimetic compounds inhibit HIV-1 
infection by induction of a short-lived 
activated state. PLOS Pathogen 5(4), 
e1000360 (2009).
94 Fouts T, Godfrey K, Bobb K et al. 
Crosslinked HIV-1 envelope-CD4 receptor 
complexes elicit broadly cross-reactive 
neutralizing antibodies in rhesus macaques. 
Proc. Natl Acad. Sci. USA 99(18), 
11842–11847 (2002).
95 Martin L, Stricher F, Missé D et al. Rational 
design of a CD4 mimic that inhibits HIV-1 
entry and exposes cryptic neutralization 
epitopes. Nat. Biotech. 21(1), 71–76 (2003).
96 Baleux F, Loureiro-Morais L, Hersant Y et al. 
A synthetic CD4-heparan sulfate 
glycoconjugate inhibits CCR5 and CXCR4 
HIV-1 attachment and entry. Nat. Chem. 
Biol. 5(10), 743–748 (2009).
97 Pantophlet R, Burton DR. Gp120: target for 
neutralizing HIV-1 antibodies. Annu. Rev. 
Immunol. 24, 739–769 (2006).
98 Phogat S, Wyatt RT, Hedestam GBK. 
Inhibition of HIV-1 entry by antibodies: 
potential viral and cellular targets. J. Intern. 
Med. 262(1), 26–43 (2007).
99 Buton DR, Pyati J, Koduri R et al. Efficient 
neutralization of primary isolates HIV-1 by a 
recombinant human monoclonal antibody. 
Science 266(5187), 1024–1027 (1994).
100 Trkola A, Purtscher M, Muster T et al. Human 
monoclonal antibody 2G12 defines a 
distinctive neutralization epitope on the gp120 
glycoprotein of human immunodeficiency virus 
type 1. J. Virol. 70(2), 1100–1108 (1996).
101 Muster T, Steindl F, Purtscher M et al. A 
conserved neutralizing epitope on gp41 of 
human immunodeficiency virus type 1. 
J. Virol. 67(11), 6642–6647 (1993).
102 Kwong PD, Wilson IA. HIV-1 and influenza 
antibodies: seeing antigens in new ways. 
Nat. Immunol. 10(6), 573–578 (2009).
103 Huber M, Olson WC, Trkola A. Antibodies for 
HIV treatment and prevention: window of 
opportunity? In: Human Antibody Therapeutics 
for Viral Disease. Current Topics 39 in 
Microbiology and Immunology (volume 317). 
Dessain SK (Ed.) Springer-Verlag, Berlin, 
Heidelberg, 39–66 (2008).
104 Balzarini J. Inhibition of HIV entry by 
carbohydrate-binding proteins. Antiviral Res. 
71(2–3), 237–247 (2006).
105 Balzarini J. Targeting the glycans of 
glycoproteins: a novel paradigm for antiviral 
therapy. Nat. Rev. Microbiol. 5(8), 583–597 
(2007).
106 Boyd MR, Gustafson KR, McMahon JB et al. 
Discovery of cyanovirin-N, a novel human 
immunodeficiency virus-inactivating protein 
that binds viral surface envelop glycoprotein 
gp120: potential applications to microbicide 
development. Antimicrob. Agents Chemother. 
41(7), 1521–1530 (1997).
107 Mori T, O’Keefe BR, Sowder II RC et al. 
Isolation and characterization of griffithsin, a 
novel HIV-inactivating protein, from the red 
alga Griffithsia sp. J. Biol. Chem. 280(10), 
9345–9353 (2005).
108 Tsai CC, Emau P, Jiang Y et al. Cyanovirin-N 
inhibits AIDS virus infection in vaginal 
transmission models. AIDS Res. Hum. 
Retroviruses 20(1), 11–18 (2004).
109 Tsai CC, Emau P, Jiang Y et al. Cyanovirin-N 
inhibits AIDS virus infection in vaginal 
transmission models. AIDS Res. Hum. 
Retroviruses 19(7), 535–541 (2003).
110 Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher 
P, Shattock RJ. Cyanovirin-N potently inhibits 
human immunodeficiency virus type 1 
infection in cellular and cervical explants 
models. J. Gen. Virol. 90(1), 234–243 (2009).
111 Hunskens D, Vermeire K, Vandemeulebroucke 
E, Balzarini J, Schols D. Safety concerns for the 
potential use of cyanovirin-N as a microbicidal 
anti-HIV agent. Int. J. Biochem. Cell Biol. 
40(12), 2802–2814 (2008).
112 O’Keefe BR, Vojdani F, Buffa V et al. Scaleable 
manufacture of HIV-1 entry inhibitor 
griffithsin and validation of its safety and 
efficacy as a topical microbicide component. 
Proc. Natl Acad. Sci. USA 106(15), 6099–6104 
(2009).
113 Jay JI, Lai BE, Myszka DG et al. Multivalent 
benzoboroxole functionalized polymers as 
gp120 glycan targeted microbicide entry 
inhibitors. Mol. Pharmaceutics 7(1), 116–129 
(2010).
114 Balzarini J, Van Laethem K, Daelemans D et al. 
Pramicidin A, a carbohydrate-binding 
nonpeptidic lead compound for treatment of 
infections with viruses with highly glycosylated 
envelopes, such as human immunodeficiency 
virus. J. Virol. 81(1), 362–373 (2007).
115 Balzarini J, Van Laethem K, François K et al. 
Pradimicin S, a highly-soluble non-peptidic 
small-size carbohydrate-binding antibiotic, is 
an anti-HIV drug lead for both microbicidal 
and systemic use. Antimicrob. Agents Chemother. 
54(4), 1425–1435 (2010).
116 Wang T, Zhang Z, Wallace OB et al. Discovery 
of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-c]-
pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine 
(BMS-378806): a novel HIV-1 attachment 
inhibitor that interferes with CD4-gp120 
interactions. J. Med. Chem. 46(20), 
4236–4239 (2003).
117 Lin PF, Blair W, Wang T et al. A small 
molecule HIV-1 inhibitor that targets the 
HIV-1 envelope and inhibits CD4 receptor 
binding. Proc. Natl Acad. Sci. USA 100(19), 
11013–11018 (2003).
118 Wang T, Yin Z, Zhang Z et al. Inhibitors of 
human immunodeficiency virus type 1 (HIV-1) 
attachment. 5. An evolution from indole to 
azaindoles leading to the discovery of 
1-(4- ben zoyl piperazin-1-yl)-2-(4,7-dimethoxy-
1H-pyrrolo[2,3-c]-pyridin-3-yl)ethane-1,2-
dione (BMS-488043), a drug candidate that 
demonstrate antiviral activity in HIV-1-infected 
subjects. J. Med. Chem. 52(23), 7778–7787 
(2009).
119 Qadir MI, Malik SA. HIV fusion inhibitors. 
Rev. Med. Virol. 20(1), 23–33 (2010).
120 Moore JP, Doms RW. The entry of entry 
inhibitors: a fusion science and medicine. Proc. 
Natl Acad. Sci. USA 100(19), 10598–10602 
(2003).
121 Liu S, Jing W, Cgeung B et al. HIV gp41 
C-terminal heptad repeat contains multi-
functional domains. J. Chem. Biol. 282(13), 
9612–9620 (2007).
HIV microbicides: state-of-the-art & new perspectives on the development of entry inhibitors | Review
www.future-science.com 1159future science group
122 Pan C, Cai L, Lu H, Qi Z, Jiang S. 
Combinations of the first and next 
generations of human immunodeficiency 
virus (HIV) fusion inhibitors exhibit a highly 
potent synergistic effect against enfuvirtide-
sensitive and-resistant HIV type 1 strains. 
J. Virol. 83(16), 7862–7872 (2009).
123 Ingallinella P, Bianchi E, Ladwa NA et al. 
Addition of a cholesterol group to an HIV-1 
peptide fusion inhibitor dramatically 
increases its antiviral potency. Proc. Natl 
Acad. Sci. USA 106(14), 5801–5806 (2009).
124 Eckert DM, Malashkevich VN, Hong LH, 
Carr PA, Kim PS. Inhibiting HIV-1 entry: 
discovery of d-peptide inhibitors that target 
the gp41 coiled-coil pocket. Cell 99(1), 
103–115 (1999).
125 Welch DB, VanDemark AP, Heroux A, 
Hill CP, Kay MS. Potent d-peptide inhibitors 
of HIV-1 entry. Proc. Natl Acad. Sci. USA 
104(43), 16828–16833 (2007).
126 Mayaux JF, Bousseau A, Pauwels R et al. 
Triterpene derivatives that block entry of 
human immunodeficiency virus type 1 into 
cells. Proc. Natl Acad. Sci. USA 91(9), 
3564–3568 (1994).
127 Lai W, Huang L, Ho P, Li Z, Montefiori D, 
Chen CH. Betulinic acid derivatives that 
target gp120 and inhibit multiple genetic 
subtypes of human immunodeficiency virus 
type 1. Antimicrob. Agents Chemother. 52(1), 
128–136 (2008).
128 Baell JB, Holloway GA. New substructure 
filters for removal of pan assay interference 
compounds (PAINS) from screening libraries 
and for their exclusion in bioassays. J. Med. 
Chem. 53(7), 2719–2740 (2010).
129 Qian K, Yu D, Chen CH et al. Anti-AIDS 
agents. 78. Design, synthesis, metabolic 
stability assessment, and antiviral evaluation 
of novel betulinic acid derivatives as potent 
anti-human immunodeficiency virus (HIV) 
agents. J. Med. Chem. 52(10), 3248–3258 
(2009).
130 Jiang S, Lu H, Liu S, Zhao Q, He Y, Debnath 
AK. N-substituted pyrrole derivatives as novel 
human immunodeficiency virus type 1 entry 
inhibitors that interfere with the gp41 
six-helix bundle formation and block virus 
fusion. Antimicrob. Agents Chemother. 48(11), 
4349–4359 (2004).
131 Liu K, Lu H, Hou L et al. Design, synthesis, 
and biological evaluation of N-carboxy-
phenylpyrrole derivatives as potent HIV 
fusion inhibitors targeting gp41. J. Med. 
Chem. 51(24), 7843–7854 (2008).
132 Wang Y, Lu H, Zhu Q, Jiang S, Liao Y. 
Structure-based design, synthesis amd 
biological evaluation of new N-carboxy-
phenylpyrrole derivatives as HIV fusion 
inhibitors targeting gp41. Bioorg. Med. Chem. 
Lett. 20(1), 189–192 (2010).
133 Smith PF, Ogundele A, Forrest A et al. 
Phase I and II study of the safety, virologic 
effect, and pharmacokinetics/
pharmacodynamics of single-dose 3-O-(3 ,´3 -´
dimethylsuccinyl)betulinic acid (bevirimat) 
against human immunodeficiency virus 
infection. Antimicrob. Agents Chemother. 
51(10), 3574–3581 (2007).
134 Stewart KD, Huth JR, Ng TI et al. 
Nonpeptide entry inhibitors of HIV-1 that 
target the gp41 coiled coil pocket. Bioorg. 
Med. Chem. Lett. 20(2), 612–617 (2010).
135 Ketas Thomas J, Schader SM, Zurita J et al. 
Entry inhibitor-based microbicides are active 
in vitro against HIV-1 isolates from multiple 
genetic subtypes. Virology 364(2), 431–440 
(2007).
136 Jenabian MA, Saidi H, Charpentier C et al. 
In vitro synergistic activity against CCR5-
tropic HIV-1 with combinations of potential 
candidate microbicide molecules HHA, 
KRV2110 and enfurvitide (T20). 
J. Antimicrob. Chemother. 64(6), 1192–1195 
(2009).
137 Auwerx J, François KO, Vanstreels E et al. 
Capture and transmission of HIV-1 by the 
C-type lectin L-SIGN (DC-SIGNR) is 
inhibited by carbohydrate-binding agents and 
polyanions. Antiviral Res. 83(1), 61–70 
(2009).
138 Gantlett KE, Weber JN, Sattentau QJ. 
Synergistic inhibition of HIV-1 infection by 
combinations of soluble polyanions with other 
potential microbicides. Antiviral Res. 75, 
188–197 (2007).
139 Yeni PG, Hammer SM, Hirsch MS et al. 
Treatment for adult HIV infection: 2004 
recommendations of the International AIDS 
Society-USA Panel, JAMA 292(2), 251–265 
(2004).
140 Seto M, Aikawa K, Miyamoto N et al. Highly 
potent and orally active CCR5 antagonists as 
anti-HIV-1 agents: synthesis and biological 
activities of 1-benzazocine derivatives 
containing a sulfoxide moiety. J. Med. Chem. 
49(6), 2037–2048 (2006).
n	 Data suggesting a possible use of 
CCR5 inhibitors in non-HIV-
mediated pathologies. 
141 Martínez-Ávila O, Hijazi K, Marradi M et al. 
Gold manno-glyconanoparticles: multivalent 
systems to block HIV-1 gp120 binding to the 
lectin DC-SIGN. Chem. Eur. J. 15(38), 
9874–9888 (2009).
	n Website
201 AIDSMEDS 
www.aidsmeds.com/articles/hiv-vivrivirov-
ccr5–2446–18031.html.
